NextCure

NEXTCURE INC

NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ADBE

ADTX

ALEC

APLS

ASLE

ASYS

ATUS

BLND

CDXS

CPHC

CPTN

ENPH

ESPR

FRGT

HRYU

INTS

MIND

MRNA

MYND

NOVA

NXTC

NXTP

OCUL

OPEN

PACB

PLUG

RDFN

RILY

RPHM

SVMH

TPIC

VCIG

VIEW

Shares of Amtech Systems, Inc.  (NASDAQ: ASYS) shares fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter sales results and issued first-quarter sales guidance below estimates.

Why Amtech Systems Shares Are Trading Higher By Over 30%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Earnings

Eurozone

Commodities

Global

U.S. stocks traded higher this morning, following the release of economic reports on Thursday.

Following the market opening Thursday, the Dow traded up 0.24% to 37,180.82 while the NASDAQ rose 0.60% to 14,822.95. The S&amp;P 500 also rose, gaining, 0.50% to 4,730.68.

US Stocks Higher; Initial Jobless Claims Fall To 202,000

Biotech

Health Care

Contracts

General

NextCure, LegoChem Biosciences Ink Collaborative Pact For Antibody Drug Conjugates

NextCure Inc

Press Releases

NextCure Provides Business Update and Reports Second Quarter 2024 Financial Results

NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024

NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting

NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting

NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results

Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta

NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference

NextCure Announces Acceptance of IND Application for LNCB74

NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers

NextCure Provides Business Update and Reports Full Year 2024 Financial Results

BioCardia

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Elevation Oncology

Equillium

GlycoMimetics

HCW Biologics

HOOKIPA Pharma

Imunon

IN8bio

Kairos Pharma

Leap Therapeutics

Moleculin Biotech

MEI Pharma

Marker Therapeutics

MetaVia

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

BiomX

Palatin Techs

SAB Biotherapeutics

Spruce Biosciences

Synlogic

HC Wainwright & Co.

Needham

Piper Sandler

Truist Securities

Comments

NextCure

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga